Market Summary
USD137.56-1.06
Delayed-0.76%
ABBV Stock Price
ABBV RSI Chart
ABBV Valuation
ABBV Price/Sales (Trailing)
ABBV Profitability
ABBV Fundamentals
ABBV Revenue
ABBV Earnings
Price Action
52 Week Range
132.74168.11
(Low)(High)
Last 7 days
-5.2%
Last 30 days
-15.0%
Last 90 days
-9.9%
Trailing 12 Months
-6.8%
ABBV Financial Health
ABBV Investor Care
Peers (Alternatives to AbbVie)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
BGNE | 322.8B | 1.6B | -3.71% | 80.48% | -168.39 | 207.32 | 77.54% | 1.62% |
ABBV | 285.4B | 56.7B | -14.98% | -6.85% | 24.12 | 4.92 | 0.03% | -39.22% |
REGN | 87.6B | 12.4B | -6.81% | 6.09% | 20.2 | 7.2 | -25.07% | -47.28% |
VRTX | 85.0B | 9.2B | 2.07% | 22.38% | 26.07 | 9.23 | 15.86% | 32.99% |
ALNY | 23.4B | 1.0B | -4.69% | 49.89% | -21.96 | 22.55 | 22.88% | -19.27% |
SRPT | 11.8B | 975.7M | 3.71% | 78.87% | -10.59 | 12.11 | 27.41% | -212.78% |
UTHR | 9.7B | 2.0B | -8.21% | -7.77% | 13.31 | 4.89 | 12.05% | 52.86% |
| MID-CAP | ||||||||
MDGL | 5.2B | - | -7.29% | 316.43% | -16.55 | 2.5K | - | -27.52% |
RARE | 3.5B | 363.3M | 17.72% | 8.70% | -4.94 | 9.63 | 3.39% | -55.81% |
BPMC | 3.5B | 204.6M | 17.81% | 4.32% | -6 | 17.05 | -7.52% | 10.65% |
MRTX | 2.2B | 18.9M | -10.74% | -34.21% | -3.03 | 118.36 | - | -16.17% |
| SMALL-CAP | ||||||||
CYTK | 3.5B | - | 0.59% | -4.18% | -8.22 | 37.46 | 34.30% | -67.22% |
CPRX | 1.2B | 256.5M | -28.21% | 63.82% | 12.26 | 4.75 | 66.85% | 120.61% |
MGNX | 315.4M | 165.3M | -25.22% | 48.69% | -3.45 | 1.91 | 130.70% | 57.97% |
CRBP | 41.8M | - | 29.00% | 3203.36% | -0.83 | 19.11 | - | -29.84% |
Financials for AbbVie
| Income Statement (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
| Revenue | -2.3% | 56,741 | 58,054 | 57,819 | 57,349 | 56,725 |
| S&GA Expenses | -0.6% | 15,172 | 15,260 | 15,103 | 14,882 | 12,634 |
| Costs and Expenses | 1.6% | 40,573 | 39,937 | 40,130 | 39,957 | 38,187 |
| EBITDA | 13.0% | 16,801 | 14,868 | 17,558 | - | - |
| EBITDA Margin | 11.6% | 0.29* | 0.26* | 0.31* | - | - |
| Earnings Before Taxes | -33.0% | 9,023 | 13,477 | 14,783 | 14,071 | 14,051 |
| EBT Margin | -9.2% | 0.23* | 0.26* | 0.25* | 0.25* | - |
| Interest Expenses | - | 2,546 | - | - | - | - |
| Net Income | -35.9% | 7,585 | 11,836 | 13,407 | 12,637 | 12,479 |
| Net Income Margin | -12.1% | 0.20* | 0.23* | 0.22* | 0.22* | - |
| Free Cahsflow | 10.6% | 24,248 | 21,921 | 22,214 | 22,047 | - |
| Balance Sheet | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
| Assets | -3.1% | 134,544 | 138,805 | 141,325 | 143,186 | 143,211 |
| Current Assets | -6.9% | 26,488 | 28,463 | 30,364 | 29,100 | 26,509 |
| Cash Equivalents | -27.1% | 6,711 | 9,201 | 11,832 | 8,521 | 6,098 |
| Inventory | 7.1% | 3,833 | 3,579 | 3,172 | 3,396 | 3,483 |
| Net PPE | -0.1% | 4,931 | 4,935 | 4,893 | 4,958 | 5,075 |
| Goodwill | 0.2% | 32,220 | 32,156 | 31,726 | 32,028 | 32,298 |
| Current Liabilities | -6.6% | 27,590 | 29,538 | 32,712 | 34,473 | 32,521 |
| . Short Term Borrowings | 0% | 1.00 | 1.00 | 10.00 | 17.00 | 12.00 |
| Long Term Debt | 0.3% | 59,292 | 59,135 | 60,399 | 61,002 | 63,522 |
| Shareholder's Equity | -22.9% | 13,303 | 17,254 | 15,994 | 14,688 | 16,314 |
| Retained Earnings | -50.0% | 2,393 | 4,784 | 4,953 | 3,516 | 5,103 |
| Additional Paid-In Capital | 1.9% | 19,619 | 19,245 | 19,056 | 18,906 | 18,731 |
| Shares Outstanding | 0.1% | 1,771 | 1,770 | 1,771 | - | - |
| Minority Interest | -12.1% | 29.00 | 33.00 | 33.00 | 35.00 | 31.00 |
| Cashflow (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
| Cashflow From Operations | -2.9% | 24,228 | 24,943 | 22,590 | 22,923 | 22,808 |
| Share Based Compensation | 1.0% | 678 | 671 | 668 | 677 | 729 |
| Cashflow From Investing | 175.3% | 469 | -623 | -1,320 | -3,221 | -3,593 |
| Cashflow From Financing | 3.1% | -24,023 | -24,803 | -21,507 | -19,632 | -22,837 |
| Dividend Payments | 1.3% | 10,178 | 10,043 | 9,851 | 9,662 | 9,465 |
| Buy Backs | 32.6% | 1,972 | 1,487 | 1,614 | 1,616 | 1,617 |
Risks for ABBV
What is the probability of a big loss on ABBV?
69.6%
Probability that AbbVie stock will be more than 20% underwater in next one year
7.7%
Probability that AbbVie stock will be more than 30% underwater in next one year.
0%
Probability that AbbVie stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does ABBV drawdown profile look like?
Y-axis is the maximum loss one would have experienced if AbbVie was unfortunately bought at previous high price.
Drawdowns
Returns for ABBV
Cumulative Returns on ABBV
16.2%
10-Year Cumulative Returns
16.5%
7-Year Cumulative Returns
11.0%
5-Year Cumulative Returns
19.2%
3-Year Cumulative Returns
What are the long-term rolling returns for ABBV?
FIve years rolling returns for AbbVie.
Annualized Returns
Which funds bought or sold ABBV recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-05-26 | Fortis Group Advisors, LLC | new | - | 281,210 | 281,210 | 0.09% |
2023-05-26 | SHEETS SMITH WEALTH MANAGEMENT | reduced | -0.46 | -52,655 | 2,808,290 | 0.43% |
2023-05-26 | CYPRESS ASSET MANAGEMENT INC/TX | reduced | -0.13 | -32,785 | 2,137,150 | 0.74% |
2023-05-26 | ProShare Advisors LLC | added | 8.11 | 14,269,700 | 230,041,000 | 0.70% |
2023-05-26 | Cravens & Co Advisors, LLC | added | 0.4 | -10,305 | 1,032,080 | 0.96% |
2023-05-25 | Empower Advisory Group, LLC | new | - | 77,659,900 | 77,659,900 | 0.35% |
2023-05-25 | Brandywine Global Investment Management, LLC | added | 93.75 | 168,896,000 | 354,358,000 | 1.43% |
2023-05-24 | Old North State Trust, LLC | added | 0.3 | -15,000 | 1,312,000 | 0.91% |
2023-05-23 | Brookfield Corp /ON/ | added | 258 | 31,712,700 | 44,232,800 | 0.17% |
2023-05-23 | MOUNTAIN PACIFIC INVESTMENT ADVISERS INC/ID | reduced | -4.65 | -186,701 | 2,938,490 | 0.21% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
AbbVie News
Schedule 13G FIlings of AbbVie
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 16, 2023 | blackrock inc. | 7.8% | 138,702,758 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 8.95% | 158,317,552 | SC 13G/A | |
| Feb 09, 2022 | vanguard group inc | 8.28% | 146,312,069 | SC 13G/A | |
| Feb 03, 2022 | blackrock inc. | 7.3% | 128,197,555 | SC 13G/A | |
| Feb 16, 2021 | capital research global investors | 2.1% | 37,921,062 | SC 13G/A | |
| Feb 10, 2021 | vanguard group inc | 8.08% | 142,563,074 | SC 13G/A | |
| Jan 29, 2021 | blackrock inc. | 7.0% | 124,423,484 | SC 13G/A | |
| Feb 14, 2020 | capital research global investors | 5.8% | 86,602,693 | SC 13G/A | |
| Feb 12, 2020 | vanguard group inc | 8.28% | 122,574,720 | SC 13G/A | |
| Feb 05, 2020 | blackrock inc. | 6.7% | 98,593,810 | SC 13G/A |
ABBV Fair Value
Recent SEC filings of AbbVie
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| May 12, 2023 | 4 | Insider Trading | |
| May 10, 2023 | 8-K | Current Report | |
| May 09, 2023 | 4 | Insider Trading | |
| May 09, 2023 | 4/A | Insider Trading | |
| May 09, 2023 | 4 | Insider Trading | |
| May 09, 2023 | 4 | Insider Trading | |
| May 09, 2023 | 4 | Insider Trading | |
| May 09, 2023 | 4 | Insider Trading | |
| May 09, 2023 | 4 | Insider Trading | |
| May 09, 2023 | 4 | Insider Trading |
Latest Insider Trading transactions for ABBV
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-05-11 | Strom Carrie C | sold (taxes) | -421,104 | 146 | -2,876 | svp & pres global allerg aesth |
2023-05-05 | BURNSIDE WILLIAM H.L. | acquired | - | - | 1,450 | - |
2023-05-05 | Alpern Robert J | acquired | - | - | 1,450 | - |
2023-05-05 | FREYMAN THOMAS C | acquired | - | - | 1,450 | - |
2023-05-05 | Roberts Rebecca B | acquired | - | - | 1,450 | - |
2023-05-05 | RAPP EDWARD J | acquired | - | - | 1,450 | - |
2023-05-05 | AUSTIN ROXANNE S | acquired | - | - | 1,450 | - |
2023-05-05 | Hart Brett J | acquired | - | - | 1,450 | - |
2023-05-05 | MEYER MELODY B | acquired | - | - | 1,450 | - |
2023-05-05 | TILTON GLENN F | acquired | - | - | 1,450 | - |
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
ABBV Income Statement
2023-03-31Condensed Consolidated Statements of Earnings (Unaudited) - USD ($) shares in Millions, $ in Millions | 3 Months Ended | |
|---|---|---|
Mar. 31, 2023 | Mar. 31, 2022 | |
| Income Statement [Abstract] | ||
| Net revenues | $ 12,225 | $ 13,538 |
| Cost of products sold | 3,986 | 4,052 |
| Selling, general and administrative | 3,039 | 3,127 |
| Research and development | 2,292 | 1,497 |
| Acquired IPR&D and milestones | 150 | 145 |
| Other operating income | (10) | 0 |
| Total operating costs and expenses | 9,457 | 8,821 |
| Operating earnings | 2,768 | 4,717 |
| Interest expense, net | 454 | 539 |
| Net foreign exchange loss | 35 | 25 |
| Other expense (income), net | 1,804 | (776) |
| Earnings before income tax expense | 475 | 4,929 |
| Income tax expense | 234 | 436 |
| Net earnings | 241 | 4,493 |
| Net earnings attributable to noncontrolling interest | 2 | 3 |
| Net earnings attributable to AbbVie Inc. | $ 239 | $ 4,490 |
| Per share data | ||
| Basic earnings per share (in dollars per share) | $ 0.13 | $ 2.52 |
| Diluted earnings per share (in dollars per share) | $ 0.13 | $ 2.51 |
| Weighted-average basic shares outstanding (in shares) | 1,770 | 1,771 |
| Weighted-average diluted shares outstanding (in shares) | 1,776 | 1,778 |
ABBV Balance Sheet
2023-03-31Condensed Consolidated Balance Sheets - USD ($) $ in Millions | Mar. 31, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets | ||
| Cash and equivalents | $ 6,711 | $ 9,201 |
| Short-term investments | 11 | 28 |
| Accounts receivable, net | 11,473 | 11,254 |
| Inventories | 3,833 | 3,579 |
| Prepaid expenses and other | 4,460 | 4,401 |
| Total current assets | 26,488 | 28,463 |
| Investments | 257 | 241 |
| Property and equipment, net | 4,931 | 4,935 |
| Intangible assets, net | 64,848 | 67,439 |
| Goodwill | 32,220 | 32,156 |
| Other assets | 5,800 | 5,571 |
| Total assets | 134,544 | 138,805 |
| Current liabilities | ||
| Short-term borrowings | 1 | 1 |
| Current portion of long-term debt and finance lease obligations | 2,800 | 4,135 |
| Accounts payable and accrued liabilities | 24,789 | 25,402 |
| Total current liabilities | 27,590 | 29,538 |
| Long-term debt and finance lease obligations | 59,292 | 59,135 |
| Deferred income taxes | 2,110 | 2,190 |
| Other long-term liabilities | 32,249 | 30,655 |
| Commitments and contingencies | ||
| Stockholders' equity | ||
| Common stock, $0.01 par value, 4,000,000,000 shares authorized, 1,821,082,016 shares issued as of March 31, 2023 and 1,813,770,294 as of December 31, 2022 | 18 | 18 |
| Common stock held in treasury, at cost, 57,113,024 shares as of March 31, 2023 and 44,589,000 as of December 31, 2022 | (6,524) | (4,594) |
| Additional paid-in capital | 19,619 | 19,245 |
| Retained earnings | 2,393 | 4,784 |
| Accumulated other comprehensive loss | (2,232) | (2,199) |
| Total stockholders' equity | 13,274 | 17,254 |
| Noncontrolling interest | 29 | 33 |
| Total equity | 13,303 | 17,287 |
| Total liabilities and equity | $ 134,544 | $ 138,805 |